Cybin to host fiscal Q2 results call Nov. 13

Executive Summary

• Cybin Inc. will report its financial results for the second quarter ended September 30, 2025, and provide a business update.
• The results and update will be presented via a conference call and webcast scheduled for Thursday, November 13, 2025, at 8 a.m. ET.
• The company is currently advancing its pipeline, including the Phase 3 study of CYB003 for major depressive disorder and the Phase 2 study of CYB004 for generalized anxiety disorder.

Key Details

• Reporting Period: Second Quarter 2025 (ended September 30, 2025).
• Event Date: November 13, 2025.
• Event Time: 8:00 a.m. Eastern Time.
• Dial-in Numbers:
  • U.S. Toll Free: 800-245-3047
  • International: 203-518-9765
• Conference ID: CYBN1113
• Webcast Access: Archived webcast available on the company's investor relations website under the events and presentations page.
• Pipeline Context:
  • CYB003: Proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder; received FDA Breakthrough Therapy designation.
  • CYB004: Proprietary deuterated N,N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder.
  • Other: Research pipeline of investigational, 5-HT-receptor focused compounds.

Notable Quotes

• No direct quotes from management were included in the provided text.